Evidence map›Paper›PMID 28104906›Full record

ReviewNature reviews. Cancer2017

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Annette T Byrne, Denis G Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K Chang and 32 more

Erratum issuedOpen access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 418 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
418citing papers in PubMed, 1 pooled it
34.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

418 citing papers in PubMed, 1 synthesis or guideline pooled it, 657 citations in OpenAlex.

  1. Pooled it
  2. Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

358 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

42 authors at 20 institutions in 11 countries.

Annette T ByrneEurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Denis G AlférezEurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK.
Frédéric AmantEurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
Daniela AnnibaliEurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
Joaquín ArribasEurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
Andrew V BiankinEurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
Alejandra BrunaEurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Eva BudinskáEurOPDX Consortium and is at the Institute of Biostatistics and Analyses, Faculty of Medicine, and Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, 625 00 Brno, Czech Republic.
Carlos CaldasEurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
David K ChangEurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
Robert B ClarkeEurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK.
Hans CleversHubrecht Institute, University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The Netherlands.
George CoukosEurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
Virginie Dangles-MarieEurOPDX Consortium and is at the Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France.
S Gail EckhardtUniversity of Colorado Cancer Center, Aurora, Colorado 80045, USA.
Eva Gonzalez-SuarezEurOPDX Consortium and is at the Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Els HermansEurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
Manuel HidalgoEurOPDX Consortium and is at Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, Massachusetts 02215, USA.
Monika A JarzabekEurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Steven de JongEurOPDX Consortium and is at the University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.
Jos JonkersEurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Kristel KemperEurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Luisa LanfranconeEurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
Gunhild Mari MælandsmoEurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
Elisabetta MarangoniEurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
Jean-Christophe MarineEurOPDX Consortium and is at the Laboratory for Molecular Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 Leuven, Belgium.
Enzo MedicoEurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
Jens Henrik NorumEurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
Héctor G PalmerEurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
Daniel S PeeperEurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Pier Giuseppe PelicciEurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
Alejandro Piris-GimenezEurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
Sergio Roman-RomanEurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
Oscar M RuedaEurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Joan SeoaneEurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
Violeta SerraEurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
Laura SoucekEurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
Dominique VanheckeEurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
Alberto VillanuevaEurOPDX Consortium and is at the Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 L'Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Emilie VinoloSeeding Science SAS, 75020 Paris, France.
Andrea BertottiEurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
Livio TrusolinoEurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
KU Leuven · BECandiolo Cancer Institute · ITCentro de Investigación Biomédica en Red de Cáncer · ESUniversité Paris Sciences et Lettres · FREuropean Institute of Oncology · ITLudwig Cancer Research · CHOslo University Hospital · NORoyal College of Surgeons in Ireland · IEUniversitat Autònoma de Barcelona · ESUniversity of Cambridge · GBUniversity of Glasgow · GBBeth Israel Deaconess Medical Center · USBreast Cancer Now · GBCancer Research UK Cambridge Center · GBCIBBIM-Nanomedicine · ESInstitut Català d'Oncologia · ESInstitut d'Investigació Biomédica de Bellvitge · ESPrincess Máxima Center · NLRECETOX · CZUniversity of Colorado Denver · US

Funding

Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos · 2014 to 2026
$20.4M
Transformative personalized vascular disrupting cancer immunotherapyR01CA156695 · NCI · UNIVERSITY OF PENNSYLVANIA · PI COUKOS, GEORGE · 2010 to 2014
$3.0M
Cancer Research UK 16465Cancer Research UK 16942Cancer Research UK 17263Cancer Research UK 20544Cancer Research UK 22533Cancer Research UK 9675Cancer Research UK C29717/A17263Chief Scientist Office SGP/1Medical Research Council MC_PC_15080Medical Research Council MR/M008975/1Medical Research Council MR/P012442/1NCI NIH HHS R01 CA156695NCI NIH HHS UM1 CA186688Wellcome Trust 10372/Z/14/Z
6 · The paper itself

Abstract

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

Indexed as

Precision MedicineXenograft Model Antitumor AssaysAnimalsBiomarkers, TumorClinical Trials as TopicDisease Models, AnimalDrug Resistance, NeoplasmHumansImmunotherapyMiceNeoplasm MetastasisNeoplasmsNeoplastic Stem CellsBiomarkers, Tumor

Identifiers

PMID28104906
OpenAlexW2574695762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.